Drug Information

Drug (ID: DG01479) and It's Reported Resistant Information

Name	NSC348884
Synonyms	NSC348884; 81624-55-7; NSC 348884; NSC-348884; N,N,N',N'-tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]ethane-1,2-diamine; NSC348884 hydrate; CHEMBL4584341; SCHEMBL12126212; DTXSID90319638; BCP09001; EX-A2342; s8149; ZINC77029766; BCP9000996; CCG-270304; CS-5564; LP01178; SDCCGSBI-0633803.P001; NSC 348884; AC-32976; BS-17560; HY-13915; C76613; N,N',N'-tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]ethane-1,2-diamine; N,N,N',N'-Tetrakis-(5-methyl-1H-benzoimidazol-2-ylmethyl)-ethane-1,2-diamine; N1,N1,N2,N2-Tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamine; (2-{bis[(6-methyl-1H-1,3-benzodiazol-2-yl)methyl]amino}ethyl)bis[(6-methyl-1H-1,3-benzodiazol-2-yl)methyl]amine Click to Show/Hide
Structure
Target	.	NOUNIPROTAC	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	11
IsoSMILES	CC1=CC2=C(C=C1)N=C(N2)CN(CCN(CC3=NC4=C(N3)C=C(C=C4)C)CC5=NC6=C(N5)C=C(C=C6)C)CC7=NC8=C(N7)C=C(C=C8)C
InChI	InChI=1S/C38H40N10/c1-23-5-9-27-31(15-23)43-35(39-27)19-47(20-36-40-28-10-6-24(2)16-32(28)44-36)13-14-48(21-37-41-29-11-7-25(3)17-33(29)45-37)22-38-42-30-12-8-26(4)18-34(30)46-38/h5-12,15-18H,13-14,19-22H2,1-4H3,(H,39,43)(H,40,44)(H,41,45)(H,42,46)
InChIKey	KZOLQEUQAFTQFM-UHFFFAOYSA-N
PubChem CID	335974

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Acute myeloid leukemia [ICD-11: 2A60]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)			Click to Show/Hide
Key Molecule: Nucleophosmin (NPM1)				[1]
Molecule Alteration	FS-deletion		p.W288fs (c.863_864)	Molecule Info
Sensitive Disease	Acute myeloid leukemia [ICD-11: 2A60.0]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	OCI-AML3 cells	Blood	Homo sapiens (Human)	CVCL_1844
	HL-60 cells	Peripheral blood	Homo sapiens (Human)	CVCL_0002
Experiment for Molecule Alteration	Immunoblotting analysis
Experiment for Drug Resistance	Colony-forming assay
Mechanism Description	The fs-deletion p.W288fs (c.863_864) in gene NPM1 cause the sensitivity of NSC348884 by aberration of the drug's therapeutic target.

References

Ref 1	Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1Blood. 2011 Sep 15;118(11):3096-106. doi: 10.1182/blood-2010-09-309674. Epub 2011 Jun 30.